Previous Scholarships

To ensure more patients receive better pain relief by reintroducing Hand-on-syringe regional anaesthesia and freeing up nurses’ time. This is achieved by distributing 3D-printed LundGrips. From colleagues to whom I have introduced the technology, I know that this can improve care within highly specialized healthcare, in A&E, but also within the armed forces and in resource-poor environments such as A&E departments in South Africa.

We want to push the frontier in molecular profiling of cells and tissues. To understand biological processes such as cellular communication, immune responses, developmental programs or the tumour microenvironment, information about cell (types) states and expression of a large number of biomarkers (more than you can get with traditional microscopy) is needed and their spatial relationships. We are developing Flowmic as we lack the optimal tool to do molecular profiling in the best possible way.

Critically low blood pressure is an acute, life-threatening condition that requires immediate action. The first thing we want to do for these patients is to administer intravenous fluids and medication to raise their blood pressure. This requires access to the bloodstream. Normally, we use a central venous catheter (CVC) – a plastic tube inserted into a vein. We administer fluids and medication through this. The primary aim of this project is to save lives and improve patients’ quality of life.

The purpose of the project is to bring a research-based digital health innovation for Parkinson’s disease closer to clinical use and commercialization. By enabling continuous, home-based monitoring of symptoms, the project aims to improve clinical decision-making, empower patients, and support healthcare systems facing increasing demand due to ageing populations. The stipend will allow me to join a startup incubator for 1 year where I will access mentoring and funding opportunities.

The overall aim of the project is to evaluate the efficacy, safety and usability of ThirstCooler for the relief of severe, prolonged thirst in patients with prescribed fluid restriction. The aim of the study is to clinically evaluate the efficacy, safety and usability of the ThirstCooler in patients, as well as to investigate its health economic value. Should the results be positive, we intend to launch our product on the market.

The development of a migraine biosensor will, for the first time, enable diagnosis based on molecular facts. A real-time biosensor that predicts attacks before symptom onset could transform care by enabling early intervention and precision medicine, where treatments match an individual’s molecular profile. This would reduce attack frequency and intensity, prevent disease progression, improve quality of life, and significantly reduce the personal, economic, and societal burden of migraine.

Diagnosing diseases in the hidden lymph nodes of the chest – known as the mediastinum – is one of the greatest challenges in modern medicine. For patients suspected of having lymphoma (cancer of the immune system) or sarcoidosis (an inflammatory systemic disease), current standard methods using fine needles are often insufficient. As these diseases alter the entire structure and architecture of the tissue, a small needle biopsy is like trying to identify an entire building by looking at a single brick; it simply provides too little information for a reliable diagnosis.

Mutations in the estrogen receptor are responsible of resistance to standard treatments, and so far no effective alternative drug regimens have been implemented in the clinic. We believe that our proteogenomic workflow can be applied to analyze clinical samples with expressed estrogen receptor mutations to derive alternative drug targets and biomarkers to validate in our model systems and additional clinical cohorts.

The purpose of the project is to find out if the technology and methods function in human kidneys as well as validate the product prototype to pave the way for efficient and successful commercialization, i.e., the first part of the clinical study. Through this, the number of donor kidneys available for transplantation is expected to rise greatly and as quickly as possible.

Our project aims to diagnose and characterise sepsis and ultimately tailor the treatment of sepsis and ARDS using protein profiles. Today, new proteomics methods (such as mass spectrometry) can analyse thousands of proteins at a time from a drop of blood. Our hope is that with protein profiling and artificial intelligence we will be able to diagnose and characterise severe sepsis and ARDS and offer each patient the best treatment.

We are developing objective and quantitative measurement tools that measure cerebellar function in combination with a modernized motor assessment test. We believe this can potentially revolutionize the way we assess and study ADHD and ASD – two diagnoses that cover several hundred thousand children in Sweden alone. In fact, our VR application may have an even wider applicability. For example, all four-year-olds in Sweden go through a motor assessment battery of tests that is used as an initial screening tool.

A large international study on ~8000 individuals from 8 countries followed for up to 20 years revealed biomarker to predict diabetes. Based on the discovery, LDcoder® was develop at Lundoch Diagnostics, which efficiently predicts the risk of diabetes at least four year before the disease actually develops. In this project, we will establish LDcoder® biomarker dried blood spot (DBS) method for blood sample home collection, which makes LDcoder® easily accessible for large population screening.

Classical tissue engineering strategies are patient-specific, thus clearly associated with inherent limits: a time-consuming graft production and a complex/costly production. Most importantly those cell-based strategy only allows for autologous use of the generated grafts. Here, we will validate the large-scale production and pre-clinical performance of a unique bone graft substitute. If successful, our cell-free cartilage product will bypass limits of existing tissue engineered strategies.

The aim of the project is to investigate the connection between diet/berries, microbiota and the effect on cognition and the pathological changes linked to Alzheimer’s disease. Above all, we hope to be able to find links to APOE4, which half of all Alzheimer’s patients have, and which is a cholesterol-carrying protein. We hope to find new mechanisms linked to APOE4, which could be exploited by dietary intervention.

The study has the potential to enable tailored treatment for depression. If the results are positive, pramipexole could be introduced as an alternative for depressed patients. There are several other ongoing or planned studies investigating similar hypotheses, namely that pramipexole may serve as a tailored treatment for anhedonia. If several independent studies show a positive effect, this could lead to a clinical breakthrough for pramipexole as a treatment for depression.

We want to make a significant difference to the lives of people with PD and their families. Our specific aim is to verify and patent a new technology for the treatment of PD. Our technology (adaptive DBS) makes it possible to adapt the treatment to the individual’s changing needs, which will improve the effect of the treatment while reducing the risk of side effects.

Most surgical interventions (biopsy collections, microinjections, implant insertions, etc.) in the brain are performed with little regard to the mechanical forces that are generated in the various brain structures. Our findings suggest that unique surgical force-mitigation strategies represent a significant advance and a unique commercial opportunity. This work is of significance to both scientific and clinical communities working in biomaterials, neurotechnology, and brain disease research.

The project aims to identify biomarkers in STBEVs that can be used to improve diagnosis and prognosis of pre-eclampsia. By identifying the specific molecular signatures of the disease, we can develop methods for personalised risk assessment and earlier intervention, which can reduce the impact of the disease and improve clinical decisions for both mothers and children. Our research has the potential to lead to new screening tools that allow for more accurate and early identification of at-risk patients who can then be followed up and, also given preventive treatment.

The glymphatic system is fundamental to the understanding of common diseases from multiple sclerosis to dementia. Currently, there is no non-invasive method to track the clearance of brain metabolites by the glymphatic system and thus link preclinical research with clinical research in this area. This work is the first time a non-invasive imaging method, applicable to both animals and humans, will measure brain metabolite clearance by the glymphatic system in real time.

In Sweden alone, there are > 30,000 strokes/year, causing major impact on individuals and society (16 B SEK/year). During the 80 000 annual ultrasound examinations, most individuals with dangerous plaques are missed, as there is currently no method to assess plaque composition. Our method is needed for 1) clinical investigations, 2) screening high-risk individuals before they suffer from a heart attack or stroke and 3) evaluating novel treatments in the pharmaceutical industry fast and cheap.